Gates Foundation Grants $17.5 Million to End Sleeping Sickness in Congo
In Antwerp, the Institute of Tropical Medicine (ITM) has secured $17.5 million (€15 million) from the Bill & Melinda Gates Foundation. The funds will fund the GAMBIT initiative, a concerted effort to eliminate the parasitic disease that kills if untreated.
Global Impact of Gates’ Funding
- Bill & Melinda Gates has financed comparable projects across continents, including Glasgow, Scotland, and North Carolina, USA.
- These ventures aim to curb various tropical diseases and improve public health worldwide.
Key Details of the GAMBIT Project
According to the Belga News Agency, the GAMBIT initiative will accelerate research and interventions targeting the tsetse fly, the vector responsible for transmitting the fatal illness in the Democratic Republic of Congo.
By harnessing advanced medical research and public health strategies, the initiative promises to make significant strides toward eradicating sleeping sickness and improving the lives of millions in the Congo region.
Most Read on Euro Weekly News
Flying Ryanair in Spain? Brace for 76 strike days – here’s what you need to know
Ground crew strike mess hits Spanish airports
Will this 300-metre steel bull become Spain’s ‘Eiffel Tower’? The Madrid village making its play
People and animals are at risk
African Sleeping Sickness
Transmission and Spread
Although rare, the disease can be transmitted from mother to child, through blood transfusions, and via sexual contact.
Regional Variations
- West Africa – predominantly human infection.
- East Africa – also affects wildlife and cattle.
Current Outlook
While cases have fallen sharply over recent decades, pinpointing the remaining infections has become increasingly complex.
Risk Assessment
Estimates indicate that about 60 million people in 36 sub-Saharan African countries are at risk, with nearly 500 000 already infected.
Why is it called that way?
Progression of the “Sleeping Sickness”
Early Signs begin with a mild fever, joint discomfort and itchy skin. As the parasites migrate to the brain, patients experience hallucinations and erratic behavior, culminating in severe pain, coma and eventual death.
Symptoms in Order
- Low‑grade fever and joint pain
- Itchy skin and escalating discomfort
- Parasite invasion of the central nervous system
- Hallucinations, disruptive behavior and excruciating pain
- Coma and, finally, death
Anticipated “Screen‑and‑Treat” Initiative (Antwerp 2029)
The upcoming project will establish a framework for a single‑dose oral therapy using acoziborole. Mobile teams will conduct antibody tests in remote communities and administer treatment immediately. Since the human host is the sole reservoir for the parasite, this approach could render eradication achievable.
Turning the tide for good
Innovative Global Health Effort Gains Momentum
Elena Nicco, a leading ITM infectious diseases specialist, hailed the new partnership as a “turning point.” She cautioned that the strategy could “turn the tide for good.”
Addressing Neglected Tropical Diseases
- Trypanosomiasis and Leishmaniasis (sleeping sickness) continue to devastate large swaths of the developing world.
- The consortium aims to fill the urgent gap in effective treatments.
Expert Opinion
Dr. Gordon Perkin, Director of the Bill & Melinda Gates Foundation’s Global Health Program, voiced optimism:
“New drugs are desperately needed, and we’re optimistic that this consortium will not only develop them but ensure that they reach infected individuals as quickly and efficiently as possible.”
Next Steps
Stakeholders will focus on:
- Accelerating drug discovery.
- Streamlining distribution networks.
- Monitoring impact on affected populations.
Collectively, these efforts promise a decisive shift in the battle against sleeping sickness.
